OKYO Pharma Ltd. Form 6-K Summary
Filing date: August 15, 2023. Reporting period: Twelve months ended March 31, 2023. OKYO Pharma Ltd. furnished the filing to report its annual financial results and provide a corporate update on its lead development program. The company files annual reports on Form 20-F.
Financial Metrics
The filing identifies financial results for the year ended March 31, 2023, but the provided filing text does not include the underlying results or clear values for revenue, profit or loss, cash flow, margins, debt, cash, liquidity, or other financial metrics. Those details were contained in Exhibit 99.1, which is referenced but not included in the supplied text.
Material Changes Versus Prior Period
The supplied text does not provide sufficient financial or operating data to determine material changes versus the prior comparable period.
Outlook, Development Program, and Risks
The filing states that the company provided a corporate update on its lead program in development. No specific development milestones, guidance, outlook, risk factors, contingencies, or unusual items are described in the supplied filing text.
Important Facts to Verify
- Review Exhibit 99.1 for the complete annual financial results for the year ended March 31, 2023.
- Verify reported cash, operating cash burn, liquidity runway, and any financing or debt information.
- Confirm the status, milestones, timing, and funding requirements of the lead development program.
- Assess any subsequent events, clinical, regulatory, or financing risks disclosed in the complete announcement.
Exhibit 99.1 was furnished rather than filed under Section 18 of the Securities Exchange Act and is not deemed incorporated by reference unless expressly stated in a subsequent filing.